Advanced searches left 3/3

Carcinoma microsatellite instability - Europe PMC

Summarized by Plex Scholar
Last Updated: 25 August 2022

* If you want to update the article please login/register

A Tumoral and Peritumoral CT-Based Radiomics and Machine Learning Approach to Predict the Microsatellite Instability of Rectal Carcinoma.

Aim: Objective: Objective Objective: Using various machine learning techniques based on tumoral and perceptumoral radiomics, as well as clinicopathological characteristics, it's possible to determine the presence of microsatellite instability of rectal carcinoma. Methods 497 RC patients were enrolled in this retrospective study. The receiver operator curve was created by DeLong's DeLong test, and the test's area under curve with a 95% confidence interval was determined to determine the model's performance. Conclusions The venous phase of CT examination was selected for further investigation because the number of radiomic features with ICC greater than 0. 75 was higher. With the AUCs of 0. 817 and 0. 726 in the preparation and validation set, the tumoral and peritumoral model by LR algorithm with minimal RSD showed good results in predicting MSI status of RCs. Both the preparation and validation procedures with AUCs of 0. 843 and 0. 8 percent were both successful.

Source link: https://europepmc.org/article/MED/35971393


Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.

We illustrate a case in which sequential administration of combination immunotherapy may be beneficial to advanced cervical cancer patients who have developed resistance to mono-immunotherapy. Following the introduction of anti-PD-1 inhibitors in patients with advanced melanoma and metastatic urothelial carcinoma, results from two new interim prospective trials using combination immunotherapy with an anti-PD-1 plus anti-CTLA-4 inhibitor have demonstrated anti-tumor activity in patients with advanced melanoma and metastatic urothelial carcinoma revealed. To date, there has been no systematic study on combined anti-PD-1 and anti-CTLA-4 therapy in patients with MSI-H tumors or advanced cervical cancer.

Source link: https://europepmc.org/article/MED/35640145

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions